EP2258402A3 - Getrocknete Zusammensetzung - Google Patents

Getrocknete Zusammensetzung Download PDF

Info

Publication number
EP2258402A3
EP2258402A3 EP10008828A EP10008828A EP2258402A3 EP 2258402 A3 EP2258402 A3 EP 2258402A3 EP 10008828 A EP10008828 A EP 10008828A EP 10008828 A EP10008828 A EP 10008828A EP 2258402 A3 EP2258402 A3 EP 2258402A3
Authority
EP
European Patent Office
Prior art keywords
dried composition
stable
trehalose
absence
serum albumin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10008828A
Other languages
English (en)
French (fr)
Other versions
EP2258402A2 (de
Inventor
Bruce Joseph Roser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quadrant Drug Delivery Ltd
Original Assignee
Quadrant Drug Delivery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quadrant Drug Delivery Ltd filed Critical Quadrant Drug Delivery Ltd
Publication of EP2258402A2 publication Critical patent/EP2258402A2/de
Publication of EP2258402A3 publication Critical patent/EP2258402A3/de
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
EP10008828A 1995-01-19 1996-01-19 Getrocknete Zusammensetzung Withdrawn EP2258402A3 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9501040.1A GB9501040D0 (en) 1995-01-19 1995-01-19 Dried composition
EP96900633A EP0871476B1 (de) 1995-01-19 1996-01-19 Getrocknete zubereitung von bluttfaktoren, enthaltend trehalose
EP03002147A EP1308170B1 (de) 1995-01-19 1996-01-19 Getrocknete Blutfaktorzusammensetzung mit Trehalose
EP08010169A EP1974741A1 (de) 1995-01-19 1996-01-19 Getrocknete, von Trehalose stabilisierte Blutfaktorzusammensetzung

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
EP96900633.7 Division 1996-07-25
EP03002147.1 Division 2003-02-03
EP08010169.4 Division 2008-06-04

Publications (2)

Publication Number Publication Date
EP2258402A2 EP2258402A2 (de) 2010-12-08
EP2258402A3 true EP2258402A3 (de) 2011-01-05

Family

ID=10768253

Family Applications (4)

Application Number Title Priority Date Filing Date
EP10008828A Withdrawn EP2258402A3 (de) 1995-01-19 1996-01-19 Getrocknete Zusammensetzung
EP03002147A Expired - Lifetime EP1308170B1 (de) 1995-01-19 1996-01-19 Getrocknete Blutfaktorzusammensetzung mit Trehalose
EP08010169A Withdrawn EP1974741A1 (de) 1995-01-19 1996-01-19 Getrocknete, von Trehalose stabilisierte Blutfaktorzusammensetzung
EP96900633A Expired - Lifetime EP0871476B1 (de) 1995-01-19 1996-01-19 Getrocknete zubereitung von bluttfaktoren, enthaltend trehalose

Family Applications After (3)

Application Number Title Priority Date Filing Date
EP03002147A Expired - Lifetime EP1308170B1 (de) 1995-01-19 1996-01-19 Getrocknete Blutfaktorzusammensetzung mit Trehalose
EP08010169A Withdrawn EP1974741A1 (de) 1995-01-19 1996-01-19 Getrocknete, von Trehalose stabilisierte Blutfaktorzusammensetzung
EP96900633A Expired - Lifetime EP0871476B1 (de) 1995-01-19 1996-01-19 Getrocknete zubereitung von bluttfaktoren, enthaltend trehalose

Country Status (15)

Country Link
US (2) US6649386B2 (de)
EP (4) EP2258402A3 (de)
JP (1) JP3898221B2 (de)
KR (1) KR100417593B1 (de)
CN (1) CN1152713C (de)
AT (2) ATE245442T1 (de)
AU (1) AU704317B2 (de)
CA (2) CA2671383C (de)
DE (2) DE69629209T2 (de)
DK (2) DK1308170T3 (de)
ES (2) ES2202425T3 (de)
GB (1) GB9501040D0 (de)
PT (2) PT871476E (de)
SI (1) SI1308170T1 (de)
WO (1) WO1996022107A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7253262B2 (en) * 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US7244824B2 (en) * 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US6964771B1 (en) 1995-06-07 2005-11-15 Elan Drug Delivery Limited Method for stably incorporating substances within dry, foamed glass matrices
US6632648B1 (en) * 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
GB9616536D0 (en) * 1996-08-06 1996-09-25 Quadrant Holdings Cambridge Co-amoxiclav dosage form
AUPO871997A0 (en) * 1997-08-25 1997-09-18 Csl Limited Dried biologically or therapeutically active preparations
EP2921180B1 (de) * 1999-02-22 2019-08-14 University of Connecticut Albuminfreie Faktor-VIII-Formulierungen
JP4340151B2 (ja) * 2001-08-10 2009-10-07 株式会社林原生物化学研究所 トレハロース又はマルチトールと金属イオン化合物との会合物
US8541002B2 (en) 2003-09-12 2013-09-24 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection
EP1755652B1 (de) 2004-03-19 2010-11-24 Baxter International Inc. Faktor ixa zur behandlung von blutungsstörungen
ATE441669T1 (de) * 2004-05-24 2009-09-15 Genvault Corp Stabile lagerung von protein und stabile lagerung von nukleinsäure in wiedergewinnbarer form
KR100624013B1 (ko) 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
US8133484B2 (en) 2006-12-15 2012-03-13 Lifebond Ltd Hemostatic materials and dressing
CA2673260A1 (en) * 2006-12-20 2008-07-03 Bayer Healthcare Llc Factor vii and viia compositions
EP1958618A1 (de) * 2007-02-15 2008-08-20 Octapharma AG Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
DK2222315T3 (da) * 2007-12-21 2013-07-08 Cangene Corp Stabiliserede faktor-ix-formuleringer indeholdende trehalose
SG187410A1 (en) * 2007-12-28 2013-02-28 Baxter Int Recombinant vwf formulations
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
JP2012501681A (ja) 2008-09-12 2012-01-26 ジェンボールト コーポレイション 生体分子の貯蔵および安定化のためのマトリックスおよび媒体
JP5781931B2 (ja) 2008-10-21 2015-09-24 バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated 凍結乾燥した組換え型vwf製剤
KR101752508B1 (ko) 2008-11-07 2017-06-29 백스터 인터내셔널 인코포레이티드 제8 인자 제형
CN102711853B (zh) 2009-12-22 2015-05-20 生命连结有限公司 用于控制交联基质的性质的酶交联剂的改性
JP2014521084A (ja) * 2011-07-13 2014-08-25 デナトール アクティエボラグ 液状生体試料の安定化法
CN102416171B (zh) * 2011-12-06 2013-12-25 中国医学科学院输血研究所 高纯度凝血酶原复合物制品干热病毒灭活过程中的保护剂
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
EP3082769B1 (de) * 2013-12-19 2018-01-31 Janssen Vaccines & Prevention B.V. Verbesserte formulierungen für virosome
DK3177317T3 (en) 2014-08-04 2020-06-15 Csl Ltd Factor viii formulation
EP3294324A1 (de) 2015-05-13 2018-03-21 Agenus Inc. Impfstoffe zur behandlung und prävention von krebs
CN107333750A (zh) * 2017-06-11 2017-11-10 成都吱吖科技有限公司 一种长时血液细胞稳定剂
KR20210005646A (ko) 2018-04-26 2021-01-14 아게누스 인코포레이티드 열쇼크 단백질-결합 펩티드 조성물 및 그의 이용 방법
WO2021001522A1 (en) 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
US20220380439A1 (en) 2020-11-09 2022-12-01 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption
WO2022261716A1 (en) * 2021-06-16 2022-12-22 Exopharm Limited Aqueous formulations for preservation of extracellular vesicles

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987000196A1 (en) * 1985-07-09 1987-01-15 Quadrant Bioresources Limited Protection of proteins and the like
EP0314095A1 (de) * 1987-10-29 1989-05-03 Rhone-Poulenc Rorer International (Holdings) Inc. Plasma- und Rekombinationsproteinformulierungen in einem Milieu hoher Ionenstärke
EP0315968A1 (de) * 1987-11-09 1989-05-17 Rhone-Poulenc Rorer International (Holdings) Inc. Plasma- und Rekombinationsproteinformulierungen in einem Milieu niedriger Ionenstärke
EP0475409A2 (de) * 1990-09-12 1992-03-18 Lifecell Corporation Verfahren und Vorrichtung zur Kryopräparation, trockene Stabilisierung und Rehydratisierung von biologischem Suspensionen
WO1994007510A1 (en) * 1992-10-02 1994-04-14 Kabi Pharmacia Ab Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
WO1995001804A1 (en) * 1993-07-05 1995-01-19 Pharmacia Ab A coagulation factor viii formulation
WO1995007713A1 (en) * 1993-09-13 1995-03-23 Baxter International Inc. Activated factor viii as a therapeutic agent and method of treating factor viii deficiency
US6171825B1 (en) * 1997-04-18 2001-01-09 Bayer Corporation Preparation of recombinant factor VIII in a protein free medium

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361509A (en) 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4495175A (en) * 1982-08-05 1985-01-22 University Of Rochester Preparation of highly purified human antihemophilic factor
FI86885C (fi) 1984-04-20 1992-10-26 Genentech Inc Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill
EP0182448A3 (de) 1984-08-24 1987-10-28 Genetics Institute, Inc. Verfahren zur Herstellung von Faktor VIII und verwandte Produkte
US4758657A (en) * 1985-07-11 1988-07-19 Armour Pharmaceutical Company Method of purifying Factor VIII:C
US4806343A (en) * 1986-03-13 1989-02-21 University Of Southwestern Louisiana Cryogenic protectant for proteins
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
US5288853A (en) * 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
WO1995003332A1 (en) * 1993-07-23 1995-02-02 Baxter International Inc. Activated human factor viii and method of preparation
US5955448A (en) * 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US7253262B2 (en) * 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
EP2921180B1 (de) * 1999-02-22 2019-08-14 University of Connecticut Albuminfreie Faktor-VIII-Formulierungen

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987000196A1 (en) * 1985-07-09 1987-01-15 Quadrant Bioresources Limited Protection of proteins and the like
US4891319A (en) * 1985-07-09 1990-01-02 Quadrant Bioresources Limited Protection of proteins and the like
EP0314095A1 (de) * 1987-10-29 1989-05-03 Rhone-Poulenc Rorer International (Holdings) Inc. Plasma- und Rekombinationsproteinformulierungen in einem Milieu hoher Ionenstärke
EP0315968A1 (de) * 1987-11-09 1989-05-17 Rhone-Poulenc Rorer International (Holdings) Inc. Plasma- und Rekombinationsproteinformulierungen in einem Milieu niedriger Ionenstärke
EP0475409A2 (de) * 1990-09-12 1992-03-18 Lifecell Corporation Verfahren und Vorrichtung zur Kryopräparation, trockene Stabilisierung und Rehydratisierung von biologischem Suspensionen
WO1994007510A1 (en) * 1992-10-02 1994-04-14 Kabi Pharmacia Ab Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
WO1995001804A1 (en) * 1993-07-05 1995-01-19 Pharmacia Ab A coagulation factor viii formulation
WO1995007713A1 (en) * 1993-09-13 1995-03-23 Baxter International Inc. Activated factor viii as a therapeutic agent and method of treating factor viii deficiency
US6171825B1 (en) * 1997-04-18 2001-01-09 Bayer Corporation Preparation of recombinant factor VIII in a protein free medium

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"AlphaNine SD / Alphanate / Pr ofilnine SD", INTERNET CITATION, XP002263525, Retrieved from the Internet <URL:http://www.alphather.com/products /ins_alhpa.htm> [retrieved on 19990719] *
B. ROSER: "Trehalose drying: a novel replacement for freeze-drying", BIOPHARM., vol. 4, no. 8, 1991, pages 47 - 53, XP000569065 *
BOEDEKER B G D: "Production processes of licensed recombinant factor VIII preparations", SEMINARS IN THROMBOSIS AND HEMOSTASIS 2001 UNITED STATES, vol. 27, no. 4, 2001, pages 385 - 394, XP002263524, ISSN: 0094-6176 *
BUNDESVERBAND DE PHARMAZEUTISCHEN INDUSTRIE E.V. (ED.): "Rote Liste 1994", 1994, EDITIO CANTOR, AULENDORF/WÜRTT., DE, XP002263526 *
COLACO C ET AL: "EXTRAORDINARY STABILITY OF ENZYMES DRIED IN TREHALOSE: SIMPLIFIED MOLECULAR BIOLOGY", BIO/TECHNOLOGY, NATURE PUBLISHING CO. NEW YORK, US, vol. 10, no. 9, 1 September 1992 (1992-09-01), pages 1007 - 1011, XP000568746, ISSN: 0733-222X *
J.L. CLELAND, EDITOR: "ACS Symposium Series 567. Formulation and Delivery of Proteins and Peptides. Chapter 14.", 1994, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, XP002002130 *

Also Published As

Publication number Publication date
ES2202425T3 (es) 2004-04-01
US20020128207A1 (en) 2002-09-12
EP1308170A3 (de) 2004-03-03
ATE413885T1 (de) 2008-11-15
DE69629209D1 (de) 2003-08-28
KR100417593B1 (ko) 2004-04-30
US6649386B2 (en) 2003-11-18
AU704317B2 (en) 1999-04-22
CA2210872C (en) 2009-09-08
PT871476E (pt) 2003-12-31
DK0871476T3 (da) 2003-11-10
AU4454096A (en) 1996-08-07
EP1308170B1 (de) 2008-11-12
EP0871476B1 (de) 2003-07-23
EP1974741A1 (de) 2008-10-01
EP2258402A2 (de) 2010-12-08
ATE245442T1 (de) 2003-08-15
ES2316658T3 (es) 2009-04-16
US7803911B2 (en) 2010-09-28
CN1152713C (zh) 2004-06-09
CA2210872A1 (en) 1996-07-25
SI1308170T1 (sl) 2009-04-30
EP1308170A2 (de) 2003-05-07
JPH11503719A (ja) 1999-03-30
DE69629209T2 (de) 2004-02-19
CA2671383C (en) 2012-04-24
GB9501040D0 (en) 1995-03-08
DK1308170T3 (da) 2008-12-15
JP3898221B2 (ja) 2007-03-28
DE69637749D1 (de) 2008-12-24
KR19980701500A (ko) 1998-05-15
CN1179107A (zh) 1998-04-15
EP0871476A1 (de) 1998-10-21
PT1308170E (pt) 2008-12-26
CA2671383A1 (en) 1996-07-25
WO1996022107A1 (en) 1996-07-25
US20090149388A1 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
EP2258402A3 (de) Getrocknete Zusammensetzung
HUP0000474A3 (en) Arylethenesulfonamide derivatives and drug composition containing the same
HUP9601566A2 (en) Therapeutic tetrahydro-isoquinolin derivatives, their intermediates and pharmaceutical compositions containing the active component
CA2181172A1 (en) Storage-stable prostaglandin compositions
AU8027291A (en) Coated solid medicament form having releasability in large intestine
AU7702291A (en) Dietary fiber, its process and physiologically active composition containing the same as an active ingredient
HUP9900881A3 (en) 4,5-diaryl oxazole derivatives and pharmaceutical compositions containing them
AU6636598A (en) Novel 3,4-dialkoxyphenyl derivatives and the use thereof
AU646942B2 (en) 3,4,N-trisubstituted-4,5-dihydro-1H-pyrazole-1-carboxamides and their use as insecticides
PL320916A1 (en) Derivatives of piperasino 2,5-dione as modulators of drug-fastness in respect to amny drugs
HUP9801256A3 (en) 5&#39;-deoxy-cytidine derivatives, preparation and use thereof and pharmaceutical compositions
AU3720193A (en) Hydroisoindolines and hydroisoquinolines as psychotropic drugs
HUP9903459A3 (en) Oxa- and tiabicyclo[3.1.0]hexane-carboxylic acids, process for their preparation and pharmaceutical compositions of the same
AU5980590A (en) 5-substituted 1,3,4-thiadizole derivatives, their preparation and their use as pesticides
USD370972S (en) Decoy for whitetail deer
IL117806A0 (en) 1,3-Dihydro-2h-imidazol-2-one derivatives their preparation and pharmaceutical compositions containing them
AU6944696A (en) Novel phenylacetic acid derivatives and medicinal composition containing the same
AU1380397A (en) Injectable pharmaceutical composition comprising ursodesoxycholic acid or tauroursodesoxycholic acid, strong base and tromethamol
IL124415A (en) N, n&#39;-bridged bisindolylmaleimides, their preparation and pharmaceutical compositions containing them
PL310146A1 (en) Application of 1,4-dihydropyridino-3,5-dicarboxylic esters as drugs as well as novel active substances and drugs
AU4318397A (en) Novel 2,4-dioxopyrrolidine and 2,4-dioxotetrahydrofuran derivatives and medicines containing the same as the active ingredient
CA2103666A1 (en) Products containing verapamil and trandolapril
AU1939697A (en) Physiologically active substances tkr1785&#39;s, process for the preparation thereof, and microbe
HUP9601918A3 (en) N,n-diethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2-propanamine dimaleate and pharmaceutical composition containing the same
PL313116A1 (en) Application of n-alkalated 1,4-dihydropridinocarboxylic esters as drugs

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

17P Request for examination filed

Effective date: 20100909

AC Divisional application: reference to earlier application

Ref document number: 1308170

Country of ref document: EP

Kind code of ref document: P

Ref document number: 1974741

Country of ref document: EP

Kind code of ref document: P

Ref document number: 0871476

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Extension state: LT LV SI

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Extension state: LT LV SI

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/26 20060101ALI20101129BHEP

Ipc: A61K 38/37 20060101AFI20101129BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1147418

Country of ref document: HK

17Q First examination report despatched

Effective date: 20150924

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160205

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1147418

Country of ref document: HK